Detail Information of Exogenous Modulation
General Information of Drug Transporter (DT) | |||||
---|---|---|---|---|---|
DT ID | DTD0170 Transporter Info | ||||
Gene Name | SLC25A12 | ||||
Transporter Name | Calcium-binding mitochondrial carrier protein Aralar1 | ||||
Gene ID | |||||
UniProt ID | |||||
Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM) | |||||
---|---|---|---|---|---|
Chemical Compound |
|||||
DT Modulation1 |
Cisplatin affects the reaction Piroxicam results in decreased expression of SLC25A12 mRNA | [2] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation1 |
NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC25A12 mRNA | [24] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation1 |
NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC25A12 mRNA | [24] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation1 |
NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC25A12 mRNA | [24] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
2,3,5-(triglutathion-S-yl)hydroquinone |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
2,3,5-(triglutathion-S-yl)hydroquinone results in increased ADP-ribosylation of SLC25A12 protein | [23] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide |
5 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC25A12 mRNA | [24] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC25A12 mRNA | [24] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation3 |
NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC25A12 mRNA | [24] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation4 |
NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC25A12 mRNA | [24] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation5 |
NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC25A12 mRNA | [24] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of SLC25A12 mRNA | [25] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
aristolochic acid I |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
aristolochic acid I results in decreased expression of SLC25A12 mRNA | [26] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
benzo(e)pyrene |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
benzo(e)pyrene results in decreased methylation of SLC25A12 intron | [27] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
bisphenol A |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
bisphenol A results in increased expression of SLC25A12 protein | [22] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
bisphenol AF |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
bisphenol AF results in increased expression of SLC25A12 protein | [22] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Cisplatin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Cisplatin affects the reaction Piroxicam results in decreased expression of SLC25A12 mRNA | [2] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
cobaltous chloride |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
cobaltous chloride results in decreased expression of SLC25A12 mRNA | [28] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
dicrotophos |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
dicrotophos results in decreased expression of SLC25A12 mRNA | [17] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
di-n-butylphosphoric acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
di-n-butylphosphoric acid affects the expression of SLC25A12 mRNA | [29] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
dorsomorphin |
5 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC25A12 mRNA | [24] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC25A12 mRNA | [24] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation3 |
NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC25A12 mRNA | [24] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation4 |
NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC25A12 mRNA | [24] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation5 |
NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC25A12 mRNA | [24] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
entinostat |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
entinostat results in increased expression of SLC25A12 mRNA | [6] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC25A12 mRNA | [24] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
epigallocatechin gallate |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
potassium chromate(VI) co-treated with epigallocatechin gallate results in decreased expression of SLC25A12 mRNA | [30] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Methapyrilene |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Methapyrilene results in decreased methylation of SLC25A12 intron | [27] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
obeticholic acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
obeticholic acid results in decreased expression of SLC25A12 mRNA | [7] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Okadaic Acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Okadaic Acid results in decreased expression of SLC25A12 mRNA | [31] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
pirinixic acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
pirinixic acid binds to and results in increased activity of PPARA protein which results in increased expression of SLC25A12 mRNA | [32] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
potassium chromate(VI) |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
potassium chromate(VI) co-treated with epigallocatechin gallate results in decreased expression of SLC25A12 mRNA | [30] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
potassium chromate(VI) results in decreased expression of SLC25A12 mRNA | [30] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Selenium |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Selenium results in decreased expression of SLC25A12 mRNA | [13] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
sodium arsenite |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
sodium arsenite results in decreased expression of SLC25A12 mRNA | [33] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
sodium arsenite results in increased expression of SLC25A12 mRNA | [21] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Thiram |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Thiram results in decreased expression of SLC25A12 mRNA | [33] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
trichostatin A |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
trichostatin A results in increased expression of SLC25A12 mRNA | [16] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
triphenyl phosphate |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
triphenyl phosphate affects the expression of SLC25A12 mRNA | [29] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Vorinostat |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC25A12 mRNA | [24] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Approved Drug |
|||||
Copper Sulfate |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Copper Sulfate inhibits the expression of SLC25A12 | [1] | |||
Piroxicam |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Piroxicam inhibits the expression of SLC25A12 | [2] | |||
Cyclosporine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Cyclosporine inhibits the expression of SLC25A12 | [3] | |||
Acetaminophen |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Acetaminophen affects the expression of SLC25A12 | [4] | |||
Carbamazepine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Carbamazepine affects the expression of SLC25A12 | [5] | |||
Panobinostat |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Panobinostat increases the expression of SLC25A12 | [6] | |||
Obeticholic acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Obeticholic acid inhibits the expression of SLC25A12 | [7] | |||
Urethane |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Urethane increases the expression of SLC25A12 | [8] | |||
Doxorubicin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Doxorubicin inhibits the expression of SLC25A12 | [9] | |||
Temozolomide |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Temozolomide inhibits the expression of SLC25A12 | [10] | |||
Ivermectin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Ivermectin inhibits the expression of SLC25A12 | [11] | |||
Valproic Acid |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Valproic Acid increases the expression of SLC25A12 | [12] | |||
Drug in Phase 3 Trial |
|||||
Vitamin E |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Vitamin E inhibits the expression of SLC25A12 | [13] | |||
Triclosan |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Triclosan inhibits the expression of SLC25A12 | [18] | |||
Drug in Phase 2 Trial |
|||||
MS-275 |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
MS-275 increases the expression of SLC25A12 | [6] | |||
Bisphenol A |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Bisphenol A increases the expression of SLC25A12 | [22] | |||
Drug in Phase 1 Trial |
|||||
Quercetin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Quercetin inhibits the expression of SLC25A12 | [14] | |||
Trichostatin A |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Trichostatin A increases the expression of SLC25A12 | [16] | |||
Sodium arsenite |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Sodium arsenite increases the expression of SLC25A12 | [21] | |||
Investigative Drug |
|||||
Phenylmercuric Acetate |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Phenylmercuric Acetate increases the expression of SLC25A12 | [6] | |||
Natural Product |
|||||
Selenium nanoparticles |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Selenium nanoparticles inhibits the expression of SLC25A12 | [13] | |||
Tobacco Smoke Pollution |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Tobacco Smoke Pollution inhibits the expression of SLC25A12 | [20] | |||
Carcinogen |
|||||
Benzo(a)pyrene |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Benzo(a)pyrene inhibits the expression of SLC25A12 | [14] | |||
Pesticide/Insecticide |
|||||
Dicrotophos |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Dicrotophos inhibits the expression of SLC25A12 | [17] | |||
Health and Environmental Toxicant |
|||||
Diethylhexyl Phthalate |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Diethylhexyl Phthalate inhibits the expression of SLC25A12 | [19] | |||
Herbicide |
|||||
Atrazine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Atrazine inhibits the expression of SLC25A12 | [15] | |||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.